Dyslipidemia Drug Indications

Dyslipidemia Drug Indications

DYSLIPIDEMIA DRUG INDICATIONS
Generic Brand Form Indications
Slow
coronary
athero-
sclerosis
Lower
total-C
Lower
LDL-C
Increase
HDL-C
Lower
apo B
Lower
TG
Sitosterol/
campe-
sterol
Reduce
risk of
CVD4
ADENOSINE TRIPHOSPHATE-CITRATE LYASE (ACL) INHIBITOR + CHOLESTEROL ABSORPTION INHIBITOR
bempedoic acid + ezetimibe Nexlizet tabs    
ANGIOPOIETIN-LIKE 3 (ANGPTL3) INHIBITOR
evinacumab-dgnb Evkeeza IV inj
BILE ACID SEQUESTRANTS
cholestyr
amine resin
pwd  
colesevelam Welchol tabs,
oral susp
colestipol Colestid tabs,
granules
CHOLESTEROL ABSORPTION INHIBITOR
ezetimibe Zetia tabs 2
FIBRATES
fenofibrate Antara caps
Fenoglide tabs
Lipofen caps
Tricor tabs
Triglide tabs
fenofibric acid Trilipix del-rel caps
LIPID-REGULATING AGENT
gemfibrozil Lopid scored tabs 1
icosapent ethyl Vascepa caps
omega-3-acid
ethyl esters
Lovaza caps
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITOR
lomitapide mesylate Juxtapid caps 3
NICOTINIC ACID DERIVATIVES
niacin ext-rel tabs
PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) INHIBITOR
alirocumab Praluent SC inj
evolocumab Repatha SC inj
Repatha Pushtronex SC inj
SMALL INTERFERING RNA (siRNA)
inclisiran Leqvio SC inj      
STATINS (HMG-CoA REDUCTASE INHIBITORS)
atorvastatin Atorvaliq oral susp
Lipitor tabs
fluvastatin caps
Lescol XL ext-rel tabs
lovastatin tabs
Altoprev ext-rel tabs
pitavastatin Livalo tabs
Zypitamag tabs
pravastatin tabs
rosuvastatin Crestor tabs 3
Ezallor Sprinkle caps  
simvastatin Zocor tabs
STATIN + CALCIUM CHANNEL BLOCKER
atorvastatin +
amlodipine
Caduet tabs
STATIN + CHOLESTEROL ABSORPTION INHIBITOR
simvastatin +
ezetimibe
Vytorin tabs
NOTES

Key:  apo B = apolipoprotein B; TG = triglycerides; total-C = total cholesterol; LDL-C = low-density lipoproteins; CVD = cardiovascular disease; IDL = intermediate-density lipoproteins; VLDL = very low density lipoproteins; HDL-C = high-density lipoproteins

1 Reduction in risk of coronary artery disease when first line agent is inadequate

2 To reduce elevated sitosterol and campesterol in homozygous familial sitosterolemia

3 Also to reduce elevated non-HDL-C (total-C minus HDL-C)

4 To reduce risk of: MI, stroke, or coronary revascularization procedures, and morbidity/mortality.

 

Not an inclusive list of medications and/or official indications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.
Listed indications may be adjuncts to other therapies, lifestyle changes and/or concomitant drugs.

(Rev. 9/2023)